Lamisil Spray, 1%, 15 ml

Name: Lamisil Spray, 1%, 15 ml
SKU: 206082
Availability: OutOfStock

€1.00

Out of stock

(E-mail when Stock is available)

EAN: 4607045190299 SKU: 206082 Categories: Antifungal, Medicine

Description

Antifungal drug for external use, which has a broad spectrum of antifungal activity. In low concentrations terbinafine has fungicidal effect against dermatophytes (Trychophyton rubrum, Trychophyton mentagrophytes, Trychophyton verrucosum, Trychophyton violaceum, Trychophyton tonsurans, Microsporum canis, Epidermophyton floccosum), molds (mainly Candida albicans) and some dimorphic fungi (Pityrosporum orbiculare).

Indications

Prevention and treatment of fungal skin infections: foot mycoses (tinea pedis); keratinization, cracking, itching and flaking of the skin caused by foot fungus; inguinal epidermophytosis (tinea craris), fungal lesions of smooth skin of the body (tinea corporis) caused by dermatophytes such as Trichophyton (incl.T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum; yeast skin infections, mainly those caused by Candida fungi (such as Candida albicans), in particular diaper rash; varicolor (Pityriasis versicolor) caused by Pityrosporum orbiculare (Malassezia furfur).

Active ingredient

Terbinafine

Composition

1 g of the spray contains:

The active ingredient:

10 mg terbinafine hydrochloride;

Associates:

macrogoal cetostearyl ether,

ethanol,
<

Purified water,

propylene glycol,

Nitrogen.

How to take, the dosage
How to take, the dosage
In adults, Lamisil® Spray can be used 1 or 2 times a day, depending on the indication. The affected areas should be thoroughly cleaned and dried before use.

Interaction
Interaction
The drug interaction of Lamisil® is currently unknown.

Special Instructions
Special Instructions
Reduction in the severity of clinical manifestations is usually noted in the first days of treatment. In case of irregular use or its premature termination there is a risk of relapse of the infection.
The drug is intended for external use only.
Avoid contact of the drug with the eyes, as it may cause irritation. In case of accidental contact the eyes should be immediately rinsed with running water. In case of persistent irritation you should consult a doctor.
In case of allergic reactions the drug should be discontinued.
Lamisil® cream for external use contains cetyl alcohol and stearyl alcohol, which may cause local allergic reactions (contact dermatitis).
Care should be taken when applying Lamisil® Spray on damaged skin areas, because the ethanol it contains may cause irritation. Lamisil® Spray is intended for external use only. Lamisil® Spray should not be used for application on the face.
Synopsis
Synopsis
Spray for external use as a clear, colorless or light yellow liquid with a characteristic odor.
Contraindications
Contraindications
Hypersensitivity to terbinafine or to any of the inactive ingredients that make up the drug; period of breast-feeding; children under 18 years of age.
With caution prescribe the drug to patients with hepatic and/or renal failure, patients with chronic alcoholism, inhibition of bone marrow hematopoiesis, tumors, metabolic diseases, occlusive vascular disease of the extremities.
Side effects
Side effects
Determination of the frequency of side effects (WHO): very frequently (≥1/10), frequently (≥1/100 and <1/10), infrequently (≥1/1000 and <1/100), rarely (≥1/10 000 and <1/1000), very rarely (<1/10 000), including individual reports.
Immune system: isolated reports – hypersensitivity reactions (rash).
Eye: rare – eye irritation.
Skin: frequently – skin peeling, itching, infrequently – skin damage, crusting, skin lesions, pigmentation disorders, erythema, burning sensation of the skin, rarely – feeling of dry skin, contact dermatitis, eczema, single reports – rash.
Local reactions: infrequent – pain, pain at the application site, irritation at the application site; rarely – exacerbation of disease symptoms. The drug may cause itching, skin flaking, pain, irritation, changes in skin pigmentation, burning, erythema and crusts. These minor symptoms should be distinguished from hypersensitivity reactions, such as rash, which occur in rare cases and require cancellation of therapy. In rare cases, the course of the fungal infection may worsen.
If any of the above side effects worsen, or if the patient notices any other side effects, he should inform the physician.
Overdose
Overdose
No cases of overdose of Lamisil® have been reported.
Symptoms: accidental oral intake of 30 ml of Lamisil® spray containing 300 mg of terbinafine hydrochloride is comparable to taking 1 tablet of Lamisil® with a dose of 250 mg (single dose for an adult).
Pregnancy use
Pregnancy use
Because clinical experience with Lamisil® cream in pregnant women is very limited, it should not be used unless absolutely necessary. During pregnancy the drug is used only if the expected benefits to the mother exceed the potential risk to the fetus. It is necessary to consult a physician.
In experimental studies terbinafine teratogenic properties have not been identified. To date, no malformations have been reported with Lamisil®.
Terbinafine is excreted with breast milk, so the drug should not be prescribed to nursing mothers. Infants should not be allowed to come into contact with any surface of the skin treated with Lamisil®.
Similarities
Similarities
Terbinafin-Teva, Exifin, Lamisil, Fungoterbin, Lamisil Dermgel, Terbisil, Binafin, Termicon, Exiter, Terbinafin, Terbix
Additional information
Weight 0.032 kg
Shelf life
3 years
Conditions of storage
At a temperature not exceeding 30 °C (do not freeze)
Manufacturer
Switzerland
Medication form
topical spray